Renata ships anticoagulant Rivaroxaban to Australia

A widely used anticoagulant drug, Rivaroxaban, has been shipped to Australia by Renata PLC, marking the first time the medicine is available in capsule form in the country.

The listed drug maker said this today in a disclosure published with the Dhaka Stock Exchange (DSE).

The product has been manufactured at a facility approved by the Therapeutic Goods Administration (TGA) of Australia, underscoring Renata's commitment to meeting stringent global regulatory standards, it said.

This achievement not only broadens patient treatment options in Australia but also reflects Renata's steady progress in expanding its international footprint, it added.

Rivaroxaban is a key therapy for preventing stroke and systemic embolism, as well as for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism.

Previously offered only as tablets, Renata's new capsule formulation is available in 15 mg and 20 mg strengths.

Today, stocks of the company dropped 0.75 percent to Tk 490.